The estimated Net Worth of Douglas A. Rich is at least $32.4 Tisíc dollars as of 1 March 2023. Mr Rich owns over 482 units of Applied Molecular Transport stock worth over $12,822 and over the last 4 years he sold AMTI stock worth over $19,540.
Mr has made over 4 trades of the Applied Molecular Transport stock since 2022, according to the Form 4 filled with the SEC. Most recently he sold 482 units of AMTI stock worth $241 on 1 March 2023.
The largest trade he's ever made was selling 4,725 units of Applied Molecular Transport stock on 1 June 2022 worth over $14,222. On average, Mr trades about 1,236 units every 34 days since 2021. As of 1 March 2023 he still owns at least 49,316 units of Applied Molecular Transport stock.
You can see the complete history of Mr Rich stock trades at the bottom of the page.
Douglas A. Rich M.B.A., M.B.A is the Chief Technical Officer at Applied Molecular Transport.
Mr A is 52, he's been the Chief Technical Officer of Applied Molecular Transport since . There are 5 older and 3 younger executives at Applied Molecular Transport. The oldest executive at Applied Molecular Transport Inc. is Dr. Randall Mrsny Ph.D., 66, who is the Co-Founder, Chief Scientific Officer & Director.
Douglas's mailing address filed with the SEC is C/O APPLIED MOLECULAR TRANSPORT INC., 450 EAST JAMIE COURT, SOUTH SAN FRANCISCO, CA, 94080.
Over the last 4 years, insiders at Applied Molecular Transport have traded over $9,673,149 worth of Applied Molecular Transport stock and bought 3,091,278 units worth $40,384,206 . The most active insiders traders include Capital Group, Llcepq Llc A..., Helen Susan Kim a Tahir Ph.D. Mahmood. On average, Applied Molecular Transport executives and independent directors trade stock every 24 days with the average trade being worth of $26,155. The most recent stock trade was executed by Tahir Ph.D. Mahmood on 22 November 2023, trading 286,320 units of AMTI stock currently worth $45,811.
Applied Molecular Transport Inc., a clinical-stage biopharmaceutical company, engages in the development of a pipeline of oral biologic product candidates to treat autoimmune, inflammatory, metabolic, and other diseases. The company's lead product candidate is AMT-101, a gastrointestinal (GI) selective oral fusion of rhIL-10 that is in Phase II clinical trial for the treatment of ulcerative colitis and related inflammatory indications. It is also involved in developing AMT-126, a GI-selective oral fusion of interleukin 22, which is in a Phase Ia clinical trial for diseases related to intestinal epithelium barrier function defects. The company, through its technology platform, designs and develops various oral biologic therapeutic modalities, such as peptides, proteins, antibodies, antibody fragments, and ribonucleic acid therapeutics. Applied Molecular Transport Inc. was founded in 2010 and is headquartered in South San Francisco, California.
Applied Molecular Transport executives and other stock owners filed with the SEC include: